Evoke Pharma

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Preparing commercial launch of GIMOTI™ in 4Q 2020 Preparing commercial launch of GIMOTI™ in 4Q 2020

Evoke Pharma Initiates Commercial Manufacturing of Gimoti™

Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020 Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020

Evoke Pharma Extends Cash Runway to 2Q 2021

AIM ImmunoTech Inc

iBio

LiveXLive Media

Cheap stocks are effectively Wall Street's casino.

5 Cheap Stocks to Buy for $10 or Less

Evoke Pharma received a nod of approval from the U.S. Food and Drug Administration, and investors can now have confidence in EVOK stock.

There’s a Major Upside Catalyst Behind Evoke Pharma Stock

Francesca's Holdings

Neonode

SINTX Technologies Inc

Last Friday was my 56th consecutive green day of trading and I ended up ending it with a gross profit of $225,000, which easily blows past the $1 million mark for the streak and is several magnitudes better than the profits from the streak it replaces.

The End Of A Record Green Streak, The Beginning Of Something New

In an update provided over the weekend, Evoke Pharma Inc. (NASDAQ: EVOK) said that the U.S.

Why This FDA Approval Puts Evoke Pharma in the Money

The binary event that was scheduled for last week panned out in favor of Evoke Pharma Inc (NASDAQ: EVOK).

Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug

Commercial Partner EVERSANA Prepares for GIMOTI Launch  Evoke Extends Cash Runway into 2021

FDA Approves Evoke’s GIMOTI™

SOLANA BEACH, Calif., May  20, 2020  (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary brand name, “Gimoti,” for the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis as resubmitted in the 505(b)(2) New Drug Application (NDA).

Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission

Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020

Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results

SOLANA BEACH, Calif., Jan.  27, 2020  (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the Gimoti™ trademark.

Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™

EVERSANA to  commercialize and distribute Gimoti in the U.S.

Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

PDUFA Target Goal Date is June 19, 2020 PDUFA Target Goal Date is June 19, 2020

FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™

SOLANA BEACH, Calif., Dec.  20, 2019  (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Gimoti™, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

Evoke Resubmits Gimoti™ New Drug Application to FDA

SOLANA BEACH, Calif., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement under Nasdaq’s Marketplace Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Accordingly, Nasdaq considers the matter closed.

Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

SOLANA BEACH, Calif., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has been granted an additional 180-day grace period to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550(a)(2). The additional compliance period ends on May 11, 2020.

Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

SOLANA BEACH, Calif., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti (metoclopramide nasal spray) with its partner Thermo Fisher Scientific, a leading global contract development and manufacturing organization that specializes in the preparation, fill and finish of nasal spray products.

Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™

Evoke Pharma, Inc. (NASDAQ: EVOK) shares have lost about 51% of their value year to date compared to the 9.4%-gain in the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) and a steeper 20% jump in the broader S&P 500 Index.

Biotech Stock On The Radar: Evoke Pharma Sets Date With FDA

During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

News for Evoke Pharma Stock (EVOK)